binding, weak DNA binding and enhanced DNA binding as compared to the binding of said wild-type AAV ~~Rep78 protein~~.

4. (Amended) The AAV Rep78 mutant of claim 2, wherein said AAV Rep78 modified protein ~~having~~ has no DNA binding or weak DNA binding to said DNA sequence and wherein the no DNA binding or weak DNA binding obtained from at least one of a papillomavirus, an AAV, an oncogene or a HIV, ~~that~~ results in the generation of higher levels of AAV DNA replication and virion numbers compared to the corresponding wild type.

5. (Amended) The AAV Rep78 mutant of claim 2, wherein said AAV Rep78 modified protein ~~having~~ has enhanced DNA binding to said DNA sequence obtained from at least one of a papillomavirus or an oncogene and wherein . . . that results in enhanced inhibition of at least one of a papillomavirus or an oncoprotein compared to the corresponding wild type.

13. (Amended) A fusion protein comprising an AAV Rep78 modified protein that binds to at least one DNA sequence obtained from one or more of a papillomavirus, an AAV, an oncogene or a HIV differently as compared to the binding of the corresponding wild-type AAV Rep78 protein as set forth in SEQ ID NO:6, and that results in AAV DNA replication and/or AAV virion production, wherein said different DNA binding is selected from the group consisting of no DNA binding, weak DNA binding and enhanced DNA binding as compared to the binding of said wild-type AAV Rep78 protein.

19. (Amended) A pharmaceutical composition comprising at least one AAV Rep78 mutant according to claim 2 with a pharmaceutically acceptable carrier.

46. (Amended) The AAV Rep78 mutant of claim 2, wherein said binding results in AAV DNA replication and/or AAV virion production.

REMARKS

Claims 2, 4-20 and 46 are pending. Claims 3 and 46 are canceled without prejudice or disclaimer and applicant reserves the right to file one or more continuing applications on any canceled subject matter. Claim 2 is amended to more clearly define the present